KalVista Pharmaceuticals (STU:4XC1) Dividends per Share : €0.00 (TTM As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Dividends per Share?

KalVista Pharmaceuticals's dividends per share for the three months ended in Jan. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jan. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Jan. 2024 was 0.00. As of today, KalVista Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

KalVista Pharmaceuticals Dividends per Share Historical Data

The historical data trend for KalVista Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Dividends per Share Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Dividends per Share

Get a 7-Day Free Trial

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of KalVista Pharmaceuticals's Dividends per Share

For the Biotechnology subindustry, KalVista Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Dividend Yield % falls into.

KalVista Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

KalVista Pharmaceuticals (STU:4XC1) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

KalVista Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Jan. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jan. 2024 )	/	EPS without NRI (Q: Jan. 2024 )
	=	0	/	-0.801
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

KalVista Pharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines